Search PubMed⌕ Search

PubMed · 12438813

Atrial flutter update.

Abstract

Typical atrial flutter has long been considered a reentrant arrhythmia, but it is only recently that the full structure of the right atrial circuit was understood, leading to de devise of ablation techniques. Recognition of the role of functional block, based on anisotropic conduction was crucial to understanding of the flutter circuit. Anisotropy at the terminal crest creates a line of block that, with the orifices of superior and inferior vena cava, constitutes the posterior boundary of the flutter circuit. The anterior boundary is the tricuspid ring, and the circuit is a ring of myocardium made by the septal and anterior right atrial walls, linked on top by the right atrial roof and inferiorly by the inferior vena cava-tricuspid ring isthmus. This isthmus, a relatively narrow part of the circuit, has become the established target for typical flutter ablation. Complete, bidirectional isthmus block is the final goal of flutter ablation. This has to be assessed, after flutter interruption, by pacing both sides of the ablation line while recording electrogram sequences from the opposite right atrial wall and the isthmus itself. Success is great in terms of prevention of flutter recurrence, however a 30% incidence of atrial fibrillation during follow-up casts a large shadow on long-term prognosis. Understanding of the myocardial abnormalities underlying atrial flutter and fibrillation will be necessary to improve this long-term outlook.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Francisco G Cosío. 2002. Atrial flutter update.. https://doi.org/10.1023/a%3A1021119905261

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

[Phenprocoumon-induced liver failure].

HISTORY: A 61-year-old woman was referred because of painless jaundice, laboratory tests having indicated hepatitis with impaired liver functions. For the past two years she had been taking phenprocoumon because she had atrial fibrillation. INVESTIGATIONS: Serological tests largely excluded infectious, autoimmune or metabolic etiology, so that the diagnosis of drug-induced hepatic disease was made. Liver biopsy showed necrotic liver cells and mild inflammatory reaction. TREATMENT AND COURSE: A perforating duodenal ulcer required urgent surgical intervention, after which liver functions further deteriorated. The patient having refused liver transplantation she was treated symptomatically (oral vitamin K. lactulose, diuretics), phenprocoumon was discontinued and her condition slowly improved. She was discharged after two months. At subsequent examination she was symptom-free, the INR was 1.41, transaminases were normal and ultrasound merely showed a slightly inhomogeneous internal structure. CONCLUSION: Phenprocoumon can cause liver damage even when the drug has been taken for prolonged periods without any problems. A careful history about previously administered drugs should be taken in any case of hepatitis of uncertain etiology.

Anticoagulants↗

INR self-management permits lower anticoagulation levels after mechanical heart valve replacement.

BACKGROUND: The Early Self Controlled Anticoagulation Trial (ESCAT I) showed that anticoagulation self-management after mechanical heart valve replacement decreased complication rates by maintaining INR levels closer to the target range than International Normalized Ratio (INR) home doctor management. The therapeutic range for the INR in that study was between 2.5 and 4.5 for all positions of prosthetic valves. ESCAT II should find out whether lowering the target range for INR self-management would further reduce complication rates. METHODS: ESCAT II is a prospective controlled randomized (valves: St. Jude Medical Standard or Medtronic Hall, treatment: conventional/low-dose) multicenter study with 3,300 patients. We present interim results of 1,818 patients. 908 were categorized as having a low-dose target range, which was INR 1.8 to 2.8 for prostheses in aortic position and 2.5 to 3.5 for prostheses in mitral position or in combined valve replacement. The control group (conventional group) with 910 patients aimed at an INR of 2.5 to 4.5 for all valve positions. RESULTS: In the conventional group, 74% of INR values measured were within the therapeutic range. In the low-dose group, 72% of the values were within that range. The linearized thromboembolism rate (% per patient year) was 0.21% for both groups. The bleeding complication rate was 0.56% in the low-dose regimen group versus 0.91% in the conventional group. CONCLUSIONS: Early onset INR self-management under oral anticoagulation after mechanical heart valve replacement enables patients to keep within a lower and smaller INR target range. The reduced anticoagulation level resulted in fewer grade III bleeding complications without increasing thromboembolic event rates.

Anticoagulants↗